Key takeaways
- • Kaiser is an integrated HMO — prescriber, pharmacy, and formulary all sit inside Kaiser, and each region runs its own formulary; verify with your specific plan and current formulary
- • T2D GLP-1s (Ozempic, Mounjaro, Rybelsus) are commonly covered when T2D is documented and step therapy is met; off-label weight-loss use is not covered; verify with your specific plan and current formulary
- • Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) are covered only when your employer or individual benefit includes an obesity-drug rider — many Kaiser plans exclude them; verify with your specific plan and current formulary
- • Kaiser Senior Advantage members are subject to the Medicare Part D weight-loss exclusion (SSA §1860D-2(e)(2)(A)), with a narrow exception for non-weight-loss FDA indications such as Wegovy (SELECT cardiovascular) or Zepbound (OSA); verify with your specific plan and current formulary
- • Prior auth, step therapy, and BMI/comorbidity documentation are the norm — denials can be appealed internally and then escalated to state Independent Medical Review
How Kaiser Permanente approaches GLP-1 coverage
Kaiser Permanente operates as a closed integrated system: the Permanente prescriber, Kaiser pharmacy, and regional formulary (NorCal, SoCal, Northwest, Colorado, Mid-Atlantic, Georgia, Hawaii, Washington) all interact under one benefit. Each region runs its own formulary committee, so a GLP-1 covered in one region may sit on a different tier or be excluded in another; verify with your specific plan and current formulary. Kaiser also administers fully-insured commercial, ACA Marketplace, and self-funded employer (ASO) plans where the employer can exclude obesity drugs entirely. For T2D GLP-1s (Ozempic, Mounjaro, Rybelsus), Kaiser typically requires documented T2D, A1c thresholds, and step therapy (often metformin first); verify with your specific plan and current formulary. For weight-loss agents (Wegovy, Zepbound, Saxenda), coverage hinges on whether your benefit includes an obesity-drug rider — many do not — and tight BMI plus comorbidity prior-auth criteria apply when coverage exists; verify with your specific plan and current formulary.
Statutory and structural notes
Kaiser commercial plans are not bound by the Medicare Part D weight-loss exclusion (SSA §1860D-2(e)(2)(A)), which applies only to Medicare. ACA essential health benefits do not require weight-loss drug coverage, so Kaiser Marketplace plans may lawfully exclude them. Self-funded employer plans are governed by ERISA and the employer's plan document. Kaiser Senior Advantage (Medicare Advantage) members remain subject to the Part D weight-loss exclusion, with a narrow exception for non-weight-loss FDA indications (Wegovy SELECT cardiovascular; Zepbound OSA).
Typically considered for coverage
The list below reflects general patterns observed across Kaiser Permanenteplan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.
- Ozempic (semaglutide) for documented T2D, subject to regional formulary tier and step therapy — verify with your specific plan and current formulary
- Mounjaro (tirzepatide) for documented T2D, often with prior authorization — verify with your specific plan and current formulary
- Rybelsus (oral semaglutide) for T2D on select regional formularies — verify with your specific plan and current formulary
- Trulicity (dulaglutide) for T2D where retained on the regional formulary — verify with your specific plan and current formulary
- Wegovy or Zepbound for weight management only when your specific employer or individual plan includes an obesity-drug benefit and BMI/comorbidity criteria are met — verify with your specific plan and current formulary
Typically excluded
- Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) under Kaiser plans whose employer/benefit design excludes obesity pharmacotherapy
- Off-label weight-loss prescribing of T2D-labeled GLP-1s (Ozempic, Mounjaro, Rybelsus) without a T2D diagnosis
- Most Kaiser Senior Advantage (Medicare Advantage) coverage of GLP-1s for weight loss, per the Medicare Part D statutory exclusion (SSA §1860D-2(e)(2)(A))
- Compounded semaglutide/tirzepatide, which Kaiser does not dispense through its in-house pharmacies
- Brand-name GLP-1s when a preferred alternative exists and step therapy has not been completed
Prior authorization
Prior authorization is commonly required for GLP-1 medications under Kaiser Permanente plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.
Appeal strategy if denied
Request the written denial and cited UM criterion; have your Permanente prescriber file a Coverage Determination or Formulary Exception with chart notes (diagnosis, BMI, comorbidities, prior therapies). If denied, file a Level 1 internal appeal by the deadline, then a Level 2, then escalate to state Independent Medical Review (in California, free DMHC IMR often overturns obesity-drug denials when guideline-supported). Senior Advantage members follow Part D redetermination and IRE pathways.
GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.